Pluri Inc (PLUR) Stock Price, Quote & News

Company Profile

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatme...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 74 710 8600

Website: www.pluri-biotech.com

Address:

MATAM Advanced Technology Park, Building No. 5, Haifa, Israel

PLURI_JUGGERNAUT_ Feb. 3 at 10:30 PM

$PLUR BUCKLE-UP !!! https://www.youtube.com/watch?v=FYYOqaOF5V8

0 · Reply

PLURI_JUGGERNAUT_ Feb. 3 at 4:34 PM

$PLUR Pluri's Alejandro Weinstein on the future of cell-based technology https://www.msn.com/en-us/technology/biotechnology/pluri-s-alejandro-weinstein-on-the-future-of-cell-based-technology/vi-AA1Vw2q8?ocid=BingNewsSerp

0 · Reply

PLURI_JUGGERNAUT_ Jan. 28 at 10:51 AM

$PLUR The New Business Model: From Licensing to Value Creation A critical component of this strategy is shifting from a passive licensing model to an active value-creation model. Rather than out-licensing technology for future royalties, Pluri is now focused on building independent companies. The plan involves developing robust go-to-market strategies for each vertical and eventually spinning them off, taking them public, or engaging in M&A. Weinstein is moving the company into active M&A to generate immediate value for shareholders. https://www.citybiz.co/article/799013/the-new-picasso-strategy-pluri-inc-unlocks-hidden-asset-value-through-vertical-focus/

0 · Reply

PLURI_JUGGERNAUT_ Jan. 26 at 1:50 PM

$PLUR Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard Setting The Stage !!! https://www.prnewswire.com/news-releases/landmark-fda-move-first-quality-control-protocol-for-mesenchymal-stromal-cells-mscs-sets-new-therapeutic-standard-302668816.html

0 · Reply

WatchTheseTickers Jan. 22 at 11:38 PM

$AIRI $CABR $PLUR $SNSE $YYAI All eyes on 🚨SVRE🚨 next week could be crazy! Top invention of 2025 and it’s not priced in SVRE is flying under the radar. Named Top Inventions of 2025 and trading on a microscopic 900K float. This is a true 10x+ setup ‼️‼️🚀🚀🚀

1 · Reply

Digitalization2026 Jan. 22 at 10:59 PM

$AIRI 👀 🤫 After Hours Top Gainers $YYAI $SNSE $PLUR $CABR

1 · Reply

topstockalerts Jan. 22 at 10:26 PM

After Hours Top Gainers PT2 $YYAI $SNSE $PLUR $CABR $WTO

0 · Reply

BioTuesdays Jan. 22 at 5:45 PM

$PLUR has announced the completion of the first phase of its program with closely held Resbiomed Technologies OOD, a European biotechnology company developing extracellular-matrix- based biomaterials and biologics for regenerative medicine, executed through Pluri’s contract development and manufacturing division, PluriCDMO https://biotuesdays.com/2026/01/22/pluri-completes-first-phase-of-placenta-derived-biomaterials-program/

0 · Reply

PLURI_JUGGERNAUT_ Jan. 22 at 2:39 PM

$PLUR Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials https://markets.businessinsider.com/news/stocks/pluri-successfully-completes-first-phase-of-resbiomed-program-for-placenta-derived-collagen-rich-biomaterials-1035736678

0 · Reply

yl_trader Jan. 22 at 2:30 PM

$PLUR kind of cool when you are the first one to the party. :-) more news.

0 · Reply

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

May 27, 2025, 7:00 AM EDT - 9 months ago

BrainStorm Secures Key Manufacturing Partnership with Minaris for Upcoming NurOwn® Phase 3b ALS Clinical Trials

Apr 28, 2025, 8:00 AM EDT - 10 months ago

Pluri Completes Strategic Acquisition of Leading Cultivated Cacao AgFoodTech Company, Kokomodo Ltd.

Mar 5, 2025, 7:00 AM EST - 1 year ago

Pluri Announces Exclusive Collaboration Agreement with Hemafund to Enhance Ukraine's Radiation Emergency Preparedness

Feb 19, 2025, 9:01 AM EST - 1 year ago

Ever After Foods and Bühler Collaborate to Scale Cultivated Meat Production and Distribution

Jan 23, 2025, 7:15 AM EST - 1 year ago

Pluri Secures $6.5 Million Strategic Investment at Premium to Market, Enters Cacao Market Through Acquisition

$Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease$

Dec 19, 2024, 8:00 AM EST - 1 year ago

Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease

Nov 12, 2024, 1:00 PM EST - 1 year ago

Pluri Inc. to Present at November 21st Virtual Investor Summit Microcap Event

Nov 11, 2024, 6:00 AM EST - 1 year ago

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing

Jul 18, 2024, 2:30 AM EDT - 1 year ago

Pluri's CDMO Selected to Manufacture Kadimastem's Novel Cell Therapy Product Candidates

Jun 18, 2024, 12:45 PM EDT - 1 year ago

Pluri: Biotech Play With Several Opportunities Across Different Sectors

Jun 18, 2024, 6:30 AM EDT - 1 year ago

Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges

Jun 6, 2024, 6:45 AM EDT - 1 year ago

U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri's PLX-R18 Acute Radiation Syndrome Contract

May 20, 2024, 7:00 AM EDT - 1 year ago

Novel Medical Food Solution for the Elderly: Pluri & Wilk Collaborate to Develop Human Breast Milk-Derived Food Production on a Commercial Scale

May 2, 2024, 7:00 AM EDT - 1 year ago

Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment

Apr 8, 2024, 7:00 AM EDT - 1 year ago

Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method

Mar 28, 2024, 7:15 AM EDT - 2 years ago

Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences

Mar 27, 2024, 7:00 AM EDT - 2 years ago

Pluri Inc. Announces 1-for-8 Reverse Share Split

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report

Mar 19, 2024, 4:00 AM EDT - 2 years ago

Engage with Pluri's Talent: Exciting Conference Appearances Ahead

Mar 14, 2024, 7:00 AM EDT - 2 years ago

Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing

Mar 11, 2024, 7:00 AM EDT - 2 years ago

Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation

Mar 6, 2024, 7:00 AM EST - 2 years ago

Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board

Feb 28, 2024, 7:00 AM EST - 2 years ago

Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals

Jan 23, 2024, 2:00 AM EST - 2 years ago

Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis

Jan 8, 2024, 7:00 AM EST - 2 years ago

Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Pluri's PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation

Jul 13, 2023, 2:00 AM EDT - 2 years ago

Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors

Jul 11, 2023, 2:00 AM EDT - 2 years ago

U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri's PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome

Apr 27, 2023, 7:00 AM EDT - 3 years ago

Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products

Mar 13, 2023, 8:00 AM EDT - 3 years ago

Israel's Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity

Dec 22, 2022, 7:00 AM EST - 3 years ago

Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept

Dec 15, 2022, 4:05 PM EST - 3 years ago

Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

Nov 10, 2022, 7:00 AM EST - 3 years ago

Pluri wins BioTech Breakthrough Cell Innovation of the Year Award

Oct 31, 2022, 8:00 AM EDT - 3 years ago

Pluri to Present and Participate in Upcoming Conferences

Sep 29, 2022, 7:00 AM EDT - 3 years ago

Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates

Sep 6, 2022, 7:00 AM EDT - 3 years ago

€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri's PLX-PAD Cells for Osteoarthritis Treatment

Jul 25, 2022, 7:00 AM EDT - 3 years ago

Pluri CEO Issues Shareholder Update

Jul 25, 2022, 1:00 AM EDT - 3 years ago

Pluristem Therapeutics Inc. Changes its Name to “Pluri Inc.” Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

Jul 13, 2022, 9:59 AM EDT - 3 years ago

Pluristem Posts Mixed Results From Study Of Muscle Regeneration After Hip Fracture Surgery

Jul 13, 2022, 6:00 AM EDT - 3 years ago

Pluristem Reports Topline Results from its Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

Mar 28, 2022, 3:00 AM EDT - 4 years ago

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

Mar 23, 2022, 7:30 AM EDT - 4 years ago

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

Mar 8, 2022, 7:12 AM EST - 4 years ago

Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

Mar 2, 2022, 7:00 AM EST - 4 years ago

Pluristem CEO Issues Shareholder Update

Feb 24, 2022, 7:00 AM EST - 4 years ago

Pluristem Announce the Closing of its Collaboration with Tnuva Group to Establish Cultured Food Platform

Jan 10, 2022, 6:26 AM EST - 4 years ago

Biotech Pluristem, Israel-Based Tnuva Collaborate On Cultured Food Platform

Jan 10, 2022, 3:00 AM EST - 4 years ago

Biotechnology Company Pluristem, and Israel's Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform

Dec 27, 2021, 7:00 AM EST - 4 years ago

Pluristem Reports Topline Results from its Phase II Studies of Acute Respiratory Distress Syndrome Associated with COVID-19

Nov 15, 2021, 7:10 AM EST - 4 years ago

Pluristem Completes Enrollment of Its Multinational Phase III Study of Muscle Regeneration Following Hip Fracture Surgery

PLURI_JUGGERNAUT_ Feb. 3 at 10:30 PM

$PLUR BUCKLE-UP !!! https://www.youtube.com/watch?v=FYYOqaOF5V8

0 · Reply

PLURI_JUGGERNAUT_ Feb. 3 at 4:34 PM

0 · Reply

PLURI_JUGGERNAUT_ Jan. 28 at 10:51 AM

0 · Reply

PLURI_JUGGERNAUT_ Jan. 26 at 1:50 PM

0 · Reply

WatchTheseTickers Jan. 22 at 11:38 PM

1 · Reply

Digitalization2026 Jan. 22 at 10:59 PM

$AIRI 👀 🤫 After Hours Top Gainers $YYAI $SNSE $PLUR $CABR

1 · Reply

topstockalerts Jan. 22 at 10:26 PM

After Hours Top Gainers PT2 $YYAI $SNSE $PLUR $CABR $WTO

0 · Reply

BioTuesdays Jan. 22 at 5:45 PM

0 · Reply

PLURI_JUGGERNAUT_ Jan. 22 at 2:39 PM

0 · Reply

yl_trader Jan. 22 at 2:30 PM

$PLUR kind of cool when you are the first one to the party. :-) more news.

0 · Reply

yl_trader Jan. 22 at 2:24 PM

$PLUR massive news! https://finance.yahoo.com/news/pluri-successfully-completes-first-phase-141500965.html

0 · Reply

Stock_Catcher Jan. 22 at 2:15 PM

$PLUR PLUR Pluri Successfully Completes First Phase of Resbiomed Program for Placenta-Derived Collagen-Rich Biomaterials

0 · Reply

PLURI_JUGGERNAUT_ Jan. 19 at 10:40 PM

$PLUR https://www.youtube.com/watch?v=2RK8OLxucWI

0 · Reply

OfficialStocktwitsUser Jan. 19 at 6:21 PM

$PLUR RSI: 55.67, MACD: -0.0682 Vol: 0.15, MA20: 3.12, MA50: 3.36 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

PLURI_JUGGERNAUT_ Jan. 10 at 1:24 AM

$PLUR https://cellav.co/#offering

0 · Reply

PLURI_JUGGERNAUT_ Jan. 9 at 12:42 PM

$PLUR As cocoa chaos continues, Kokomodo finds its moment https://www.foodnavigator.com/Article/2026/01/07/kokomodo-rises-as-cocoa-crisis-fuels-demand-for-cellgrown-cacao/

0 · Reply

PLURI_JUGGERNAUT_ Jan. 5 at 3:46 PM

$PLUR The U.S. Food and Drug Administration (FDA) has authorized Mayo Clinic to offer mesenchymal stem cells as part of the Regenerative Nephrology Compassionate Use Program. https://www.mayo.edu/research/departments-divisions/department-internal-medicine/division-nephrology-hypertension/patient-care/regenerative-nephrology-compassionate-use-program

0 · Reply

PLURI_JUGGERNAUT_ Jan. 5 at 11:41 AM

$PLUR January Company Presentation is Out! Lots of Significant Information !!! Pay Close Attention To Pages 13,20,21 !!! https://pluri-biotech.com/presentation/

0 · Reply

Bumbleclod Jan. 2 at 5:42 PM

$PLUR Reminder for '26 newbies.........

0 · Reply

GolanShoshan Jan. 2 at 12:35 PM

$PLUR is very bad

0 · Reply

SuperGreenToday Dec. 31 at 4:49 AM

$PLUR

0 · Reply

BillionerOfKing Dec. 30 at 9:58 PM

$PLUR Current Stock Price: $2.94

0 · Reply

Market Cap	34.72M
Revenue (ttm)	1.34M
Net Income (ttm)	-22.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,685.07%
Debt to Equity Ratio	-4.87

Volume	820
Avg Vol	29,786
Day's Range	N/A - N/A
Shares Out	9.98M
Stochastic %K	95%
Beta	0.66
Analysts	Strong Buy
Price Target	$12.00